We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study.
- Authors
Badurdeen, Dilhana; Hoff, Anna Carolina; Barrichello, Sergio; Hedjoudje, Abdellah; Itani, Mohamad I.; Farha, Jad; Abbarh, Shahem; Adam, Atif; Singh, Vikesh K.; Ngamruengphong, Saowanee; Oberbach, Andreas; Khashab, Mouen A.; Neto, Manoel Galvao; Kumbhari, Vivek
- Abstract
Purpose: Weight regain after balloon retrieval is a concern with all intra-gastric balloons (IGBs). The aim of this study was to evaluate the efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, to prevent weight regain following IGB retrieval. Materials and Methods: This was a case-matched study of patients undergoing Spatz3 adjustable IGB (Spatz FGIA, Inc. NY, USA) at three outpatient clinics in Brazil between November 2015 and January 2019. Seventy-seven patients that opted to take liraglutide following IGB retrieval (IGB-L) were matched 1:1 to 198 patients that declined the medication—IGB-Alone (IGB-A). Propensity score adjustment was performed at the time of balloon retrieval on factors known to influence the choice of liraglutide. Weight and percent body fat (%BF) was measured at baseline and 9 months after IGB retrieval. % BF is defined as the total mass of fat divided by total body mass, multiplied by 100. The primary outcome was weight regain, and the secondary outcome was change in %BF 9 months after IGB retrieval. Results: Propensity score matching yielded 53 matched pairs. Weight regain to the starting point was not observed in either group. There was significantly less weight regain in IGB-L compared to IGB-A, − 1.15 ± 0.94 kg versus − 0.66 ± 0.99 kg (p = 0.010) 9 months after balloon retrieval. Additionally, %BF decline in IGB-L was superior to IGB-A − 10.83 ± 1.50 versus − 7.94 ± 2.02 (p < 0.01). There was no difference in weight regain or decline in %BF based on liraglutide dose. Conclusion: Liraglutide has an additive benefit with respect to efficacy and a reduction in body fat when commenced after IGB retrieval. Future randomized control studies will be needed to determine the optimal dose and duration of liraglutide to achieve superior outcomes.
- Subjects
NEW York (N.Y.); BRAZIL; LIRAGLUTIDE; GASTRIC banding; PROPENSITY score matching; INTRA-aortic balloon counterpulsation; FAT
- Publication
Obesity Surgery, 2021, Vol 31, Issue 3, p1204
- ISSN
0960-8923
- Publication type
Article
- DOI
10.1007/s11695-020-05117-8